Diabetes type1, Inflammatory Bowel Diseases, Juvenile Idiopathic Arthritis
Conditions
Keywords
microbiota, environmental factors, food contaminants
Brief summary
Two types of inflammatory and autoimmune diseases (excluding monogenic diseases) can be distinguished in children: those similar to adult diseases but with an early onset (type 1 diabetes, inflammatory diseases of the gastrointestinal tract, rheumatoid arthritis with anti-CCP antibodies) and those specific to children that are not described in adults (early-onset juvenile idiopathic arthritis with anti-nuclear and anterior uveitis). The familial and nosological aggregations suggest that these diseases are probably polygenically determined, and result from interactions with the environment. In a singular way, the incidence of "adult" diseases is increasing while the age of onset is getting earlier; conversely, there is no increase in early-onset juvenile idiopathic arthritis. On the other hand, the influence of early events that may alter the microbiotic environment is different for different diseases: whereas cesarean section (or early antibiotic therapy) has been shown to increase the risk of JIA and T1DM, it does not seem to change the risk of IBD. We hypothesize that environmental factors, particularly those related to diet and bacterial and fungal digestive microbiota - are different between these disease categories.
Detailed description
Exploratory pathophysiology monocentric study including an initial case-control study, followed by a cohort for cases. Controls will be siblings of cases with longitudinal follow-up. Stool samples will be collected simultaneously from the child with JIA, T1DM or IBD (case) and his/her sibling(s) (control): * at the time of diagnosis * two months after diagnosis (for children with inflammatory disease only) * one year after diagnosis (cases and controls) Tryptase level in plasma will be recorded for the child with JIA, T1DM or IBD (at the time of diagnosis, 2 months and 1 year after diagnosis)
Interventions
OTHERStool sample
Comparaison of the gut microbiota composition
Sponsors
University Hospital, Clermont-Ferrand
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 10 Years
Healthy volunteers
Yes
Inclusion criteria
CASE: \- Newly diagnosed with JIA, IBD or T1DM CONTROL: \- Brother/sister of child with pediatric onset inflammatory disease (same age category - same environment: diet, living environment)
Exclusion criteria
(case and control): * Child with antibiotic treatment in the 4 weeks preceding the stool sample * Recent digestive infectious disease (bacterial, viral, parasitic) (end of episode \< 7 days)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gut microbiota composition | Day 1 | Variation between cases and controls in gut microbiota composition (determination of the gut microbiota composition by 16S metagenomic) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Composition of the fecal volatolome | Day 1 | The volatile compounds in the samples will be analyzed via solid-phase microextraction (SPME) coupled with gas chromatography-mass spectrometry (GC-MS) |
| Variation in gut microbiota following initiation of therapy in patients newly diagnosed with JIA, IBD or T1DM. | Day 1, 2 months, 12 months | Characterization of the gut microbiota using a capture method by hybridization of the gene encoding 16S rRNA |
| Tryptasemia | Day 1, 2 months, 12 months | Variation in plasma tryptase levels during the first year of the disease |
| Fecal contamination with nanoparticles | Day 1 | measurement of titane and silicia levels in stool sample |
Countries
France
Contacts
PRINCIPAL_INVESTIGATOREtienne Merlin
University Hospital, Clermont-Ferrand
Outcome results
None listed